1Y Close · As of Aug 26, 2026
SCL Science operates in the Pharmaceuticals sector.
Legal name: SCL Science Inc.
In fiscal year 2025, SCL Science (246960) reported revenue of 22.0 billion KRW, up 364.6% from 4.7 billion KRW a year earlier.
Operating profit was -3.4 billion KRW and net income was -4.1 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 78.2 billion KRW, with a P/B of 3.33.
These figures can be verified in the DART filing (receipt no. 20260515001783).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 22.0B | -3.4B | -4.1B |
| 2024 | 4.7B | -3.7B | -3.7B |
| 2023 | 1.3B | -4.0B | -5.0B |
Recent Filings
Large Shareholding Report (General)
Semi-Annual Report (2026.06)
Sales/Supply Contract
Checks
3 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-18 | Large Shareholding Report (General) |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-10 | Sales/Supply Contract |
| 2026-08-06 | Officer/Major Shareholder Ownership Report |